Regentis Biomaterials

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

Regentis Biomaterials headquartered in Asia, operates in the Biotechnology, Health Care, Medical Device sector. The company focuses on Biotechnology and has secured $2.2B in funding across 60 round(s). With a team of 11-50 employees, Regentis Biomaterials is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Regentis Biomaterials, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.